Original Article

Serum osteoprotegerin levels associated with the aortic augmentation index in renal transplant recipients

Bang-Gee Hsu a, b, Chung-Jen Leec, Yen-Cheng Chen b, d, Guan-Jin Hob, d, Teng-Yi Lin e, Ming-Che Lee b, d, *

*Division of Nephrology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
bSchool of Medicine, Tzu Chi University, Hualien, Taiwan
cDepartment of Nursing, Tzu Chi University of Science and Technology, Hualien, Taiwan
dDepartment of Surgery, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
eDepartment of Laboratory Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan

ARTICLE INFO

Article history:
Received 5 October 2015
Received in revised form 19 November 2015
Accepted 22 December 2015
Available online 9 February 2016

Keywords:
Aortic augmentation index
Kidney transplantation
Osteoprotegerin

ABSTRACT

Objectives: Arterial stiffness is recognized as an independent risk factor for cardiovascular morbidity and mortality. Recent studies found that osteoprotegerin (OPG) is associated with arterial stiffness and may reflect endothelial dysfunction. The aim of this study was to evaluate the relationship between fasting serum OPG levels and the aortic augmentation index (AIx) in renal transplant recipients.

Materials and methods: Fasting blood samples were obtained from 66 renal transplant recipients. The aortic AIx was measured using a validated tonometry system (SphygmoCor). Serum OPG levels were measured using a commercial enzyme-linked immunosorbent assay kit.

Results: Univariate linear analysis of the aortic AIx in renal transplant recipients revealed that body fat mass ($r = 0.377$, $p = 0.002$), aortic diastolic blood pressure (DBP; $r = 0.307$, $p = 0.020$), triglycerides ($r = 0.260$, $p = 0.035$), and logarithmically transformed OPG (log-OPG; $r = 0.402$, $p < 0.001$) were positively correlated, whereas height ($r = 0.361$, $p = 0.004$) and body weight ($r = 0.212$, $p = 0.041$) were negatively correlated with the aortic AIx in renal transplant recipients. Multivariate forward stepwise linear regression analysis of the factors significantly associated with the aortic AIx showed that log-OPG ($R^2 = 0.213$, $p < 0.001$), height ($R^2 = 0.081$, $p = 0.009$), and aortic DBP ($R^2 = 0.058$, $p = 0.022$) were independent predictors of the aortic AIx in renal transplant recipients.

Conclusion: These results suggest that the serum fasting OPG level is associated with the aortic AIx in renal transplant recipients.

Copyright © 2016, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Cardiovascular (CV) disease is still a major cause of mortality in renal transplant recipients. This is partially attributed to nonclassic CV disease risk factors including arterial stiffness, an established independent predictor of mortality in several patient populations [1]. The European Society of Cardiology Working Group described the importance of peripheral noninvasive vascular biomarkers for primary and secondary CV disease prevention [2]. Among them, noninvasive methods to assess central hemodynamics/wave reflections such as the aortic augmentation index (AIx) of central blood pressure have been widely used as clinical indices of arterial stiffness [2,3]. The AIx (augmentation pressure-to-pulse pressure ratio) is a measure of the contribution that wave reflection makes to the central pressure wave: it is defined as the difference between the second and first peaks corresponding to the systolic blood pressure (SBP) and expressed as a percentage of the pulse pressure. Thus, the AIx is an indirect measure of central arterial stiffness, but mainly a direct measure of central wave reflection [4].

Vascular calcification is a tightly controlled process similar to bone formation, where mineralization of the internal elastic lamina and elastic fibers in the media results in vascular stiffening [5–7].
Osteoprotegerin (OPG) is considered a vascular calcification inhibitor. It can prevent vascular calcification by blocking the bone remodeling process in vascular tissue and by neutralizing the proapoptotic actions of tumor necrosis factor–related apoptosis-inducing ligand [6]. Elevated serum OPG is an independent predictor of death from any cause or of CV death among renal transplant recipients [8]. In the Assessment of Lescol in Renal Transplantation study, elevated serum OPG level was also found to be independently associated with renal events, CV events, and mortality in renal transplant recipients [9]. Our previous studies noted that high OPG levels were associated with central arterial stiffness measured by carotid–femoral pulse wave velocity in hypertensive patients and renal transplant recipients [10,11]. The aim of this study was to determine the relationship between fasting serum OPG levels and arterial stiffness, as measured by the aortic AIx, in renal transplant recipients.

2. Materials and methods

2.1. Patients

Between May and August 2013, 66 renal transplant recipients from a medical center in Hualien, Taiwan, were enrolled in this study. The Human Subjects Institutional Review Board of Tzu Chi University and General Hospital approved this study. Patients were excluded if they had any acute infection, malignancy, acute rejection, acute myocardial infarction, or pulmonary edema at the time of blood sampling as well as if they had an arterial–venous shunt or had received a graft in the hands. Patients using medications related to calcium, active vitamin D metabolites, bisphosphonates, teriparatide, or estrogen were excluded as were those who refused to provide informed consent.

2.2. Anthropometric analysis

The participants' weights were measured in light clothing and without shoes to the nearest 0.5 kg, and their height was measured to the nearest 0.5 cm. Body mass index was calculated as the weight in kilogram divided by the height in meter square [10–12]. Bioimpedance measurements of fat mass were performed at the bedside according to the standard tetrapolar whole-body (hand-foot) technique, using a single-frequency (50 kHz) analyzer (Biodynamic-450, Biodynamics Corporation, Seattle, WA, USA). Measurements were carried out by the same operator for all patients.

2.3. Biochemical investigations

Fasting blood samples (approx. 5 mL collected) of approximately 0.5 mL for hemoglobin and white blood cell counts (Sysmex K-1000, Sysmex American, Mundelein, IL, USA) were immediately centrifuged at 3000g for 10 minutes. Serum levels of blood urea nitrogen (BUN), creatinine (Cre), fasting glucose, total cholesterol, triglycerides (TGs), high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, total calcium, and phosphorus were measured using an autoanalyzer (cobas integra 800, Roche Diagnostics, Basel, Switzerland) [10–12]. Serum OPG levels (eBioscience Inc., San Diego, CA, USA) were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) [10–12]. The limit of detection calculated as the logarithm base 10; after this transformation, the log-glucose, log-BUN, log-Cre, log-iPTH, and log-OPG were normally distributed. Clinical variables that correlated with the aortic AIx values in renal transplant recipients were first evaluated by univariate linear regression analysis. Variables that were significantly associated with the aortic AIx in the renal transplant recipients were tested for independence by multivariate forward stepwise regression analysis. All data were analyzed using SPSS for Windows (version 19.0; SPSS Inc., Chicago, IL, USA). A p value of less than 0.05 was considered statistically significant.

2.4. Pulse wave analysis and aortic AIx assessment

Patients were positioned supine and allowed to rest for 10 minutes prior to the test. Consumption of food, drink, alcohol, and tobacco was not restricted, but patients were not allowed to sleep or talk during the testing procedure. Pulse wave analysis was performed by applanation tonometry on the right radial artery and analyzed by SphygmoCor software (SphygmoCor system, AtCor Medical, West Ryde, Australia) [10,11]. This software calculates a number of major indices including the aortic AIx aortic SBP, and aortic diastolic blood pressure (DBP). Pulse pressure was calculated by subtracting the DBP from the SBP.

2.5. Statistical analysis

Data were tested for normal distribution using the Kolmogorov–Smirnov test. Data were expressed as means ± standard deviation for normally distributed data and as medians and interquartile ranges for non-normally distributed data. The glucose, BUN, Cre, iPTH, and OPG datasets showed skewed non-normal distributions, and therefore, were recalculated by transformation to the logarithm base 10; after this transformation, the log-glucose, log-BUN, log-Cre, log-iPTH, and log-OPG were normally distributed.

The clinical and laboratory anthropometric and biochemical data of the 66 renal transplant recipients are presented in Table 1. Table 2 shows that 40 patients had diabetes (60.6%) and 17 had hypertension (25.8%). The immunological medications prescribed to the renal transplant recipients included tacrolimus (n = 38, 57.6%), mycophenolate mofetil or mycophenolic acid (n = 49, 74.2%), steroids (n = 54, 81.8%), rapamycin (n = 11, 16.7%), and cyclosporine (n = 17, 25.8%). There were no statistically significant differences in aortic AIx values based on sex, transplantation model, diabetes, hypertension, or use of the immunological medications listed.

Univariate linear analysis of the aortic AIx values of the 66 renal transplant recipients is presented in Table 3. Body fat mass (r = 0.377, p = 0.002), aortic DBP (r = 0.307, p = 0.020), TGs (r = 0.260, p = 0.035), and log-OPG (r = 0.402, p < 0.001) were positively correlated, whereas height (r = 0.361, p = 0.004) and body weight (r = 0.212, p = 0.041) were negatively correlated with the aortic AIx in these patients.

Multivariate forward stepwise linear regression analysis of the variables that were significantly associated with the aortic AIx levels in univariate analysis showed that log-OPG (β = 0.397, R² = 0.213, p < 0.001), height (β = −0.260, R² = 0.081, p = 0.009), and aortic DBP (β = 0.243, R² = 0.058, p = 0.022) were independent predictors of the aortic AIx in these patients (Table 4).
Clinical and analytical characteristics of the 66 renal transplant recipients.

| Characteristic                  | n (%)               | Augmentation index (%) | p   |
|---------------------------------|---------------------|------------------------|-----|
| Anthropometric data             |                     |                        |     |
| Age (years)                     | 51.59 ± 9.32        |                        | 0.012|
| KT duration (months)            | 71.30 ± 43.55       |                        |     |
| Height (cm)                     | 162.32 ± 8.36       |                        |     |
| Body weight (kg)                | 62.36 ± 12.65       |                        |     |
| Body mass index (kg/m^2)        | 23.78 ± 4.19        |                        |     |
| Waist circumference (cm)        | 84.88 ± 11.20       |                        |     |
| Body fat mass (%)               | 29.06 ± 6.39        |                        |     |
| Aortic SBP (mmHg)               | 139.48 ± 16.51      |                        |     |
| Aortic DBP (mmHg)               | 87.24 ± 10.57       |                        |     |
| Pulse pressure (mmHg)           | 52.24 ± 12.69       |                        |     |
| Augmentation index (%)          | 18.17 ± 11.09       |                        |     |
| Biochemical data                |                     |                        |     |
| White blood count (×1000/μL)    | 7.02 ± 2.46         |                        |     |
| Hemoglobin (g/dL)               | 12.32 ± 2.29        |                        |     |
| Total cholesterol (mg/dL)       | 195.94 ± 46.83      |                        |     |
| Triglyceride (mg/dL)            | 144.13 ± 108.62     |                        |     |
| HDL-C (mg/dL)                   | 52.27 ± 16.42       |                        |     |
| LDL-C (mg/dL)                   | 106.60 ± 34.45      |                        |     |
| Fasting glucose (mg/dL)         | 94.50 (86.00–110.00) |                        |     |
| Blood urea nitrogen (mg/dL)     | 22.00 (17.00–34.25) |                        |     |
| Creatinine (mg/dL)              | 15.0 (1.18–20.03)   |                        |     |
| GFR (ml/min)                    | 43.38 ± 21.49       |                        |     |
| Total Calcium (mg/dL)           | 9.21 ± 1.06         |                        |     |
| Phosphorus (mg/dL)              | 3.36 ± 0.80         |                        |     |
| Calcium-phosphorus product      | 30.61 ± 6.46        |                        |     |
| iPTH (pg/mL)                    | 115.75 (70.80–155.65) |                      |     |
| Osteoporosis (mg/P)             | 3.20 (1.27–9.57)    |                        |     |

Values for continuous variables given as means ± standard deviation and variables not normally distributed given as medians and interquartile range.

DBP = diastolic blood pressure; GFR = glomerular filtration rate; HDL-C = high-density lipoprotein-cholesterol; iPTH = intact parathyroid hormone; KT = kidney transplantation; LDL-C = low-density lipoprotein-cholesterol; SBP = systolic blood pressure.

### 4. Discussion

The current results reveal that body fat mass, aortic DBP, TGs, and log-OPG were positively correlated, whereas height and body weight were negatively correlated with the aortic AIx.

### Table 2

Clinical characteristics and aortic augmentation index levels of the 66 renal transplant recipients.

| Characteristic                  | n (%)               | Augmentation index (%) | p   |
|---------------------------------|---------------------|------------------------|-----|
| Sex                             |                     |                        |     |
| Male                            | 36 (54.5)           | 15.57 ± 11.20          | 0.052|
| Female                          | 30 (45.5)           | 21.07 ± 10.41          |     |
| Diabetes                        |                     |                        |     |
| No                              | 26 (39.4)           | 15.31 ± 9.44           | 0.091|
| Yes                             | 40 (60.6)           | 20.03 ± 11.78          |     |
| Hypertension                    |                     |                        |     |
| No                              | 49 (74.2)           | 17.88 ± 11.49          | 0.722|
| Yes                             | 17 (25.8)           | 19.00 ± 10.13          |     |
| Transplantation model           |                     |                        |     |
| Cadaveric                      | 57 (86.4)           | 17.44 ± 11.47          | 0.182|
| Living                          | 9 (13.6)            | 22.78 ± 7.07           |     |
| Tacrolimus use                  |                     |                        |     |
| No                              | 28 (42.4)           | 17.18 ± 10.06          | 0.538|
| Yes                             | 38 (57.6)           | 18.89 ± 11.87          |     |
| Mycophenolate mofetil or mycophenolic acid use | 17 (25.8) | 19.65 ± 12.14 | 0.527 |
| Yes                             | 49 (74.2)           | 17.65 ± 10.79          |     |
| Steroid use                     |                     |                        |     |
| No                              | 12 (18.2)           | 19.92 ± 12.47          | 0.350|
| Yes                             | 54 (81.8)           | 17.78 ± 10.85          |     |
| Rapamycin use                   |                     |                        |     |
| No                              | 55 (83.3)           | 18.31 ± 11.28          | 0.818|
| Yes                             | 11 (16.7)           | 17.45 ± 10.58          |     |
| Cyclosporine use                |                     |                        |     |
| No                              | 49 (74.2)           | 18.53 ± 11.52          | 0.654|
| Yes                             | 17 (25.8)           | 17.12 ± 5.99           |     |

### Table 3

Correlation of aortic augmentation index levels and clinical variables by univariate linear regression analysis among the 66 renal transplant recipients.

| Variable                         | r   | p     |
|----------------------------------|-----|-------|
| Age (y)                          | 0.021| 0.868 |
| Kidney transplantation duration (mo) | 0.093 | 0.456 |
| Height (cm)                      | -0.361| 0.003 * |
| Body weight (kg)                 | -0.252| 0.041 * |
| Body mass index (kg/m^2)         | -0.155| 0.215 |
| Body fat mass (%)                | 0.377| 0.002 * |
| Aortic systolic blood pressure (mmHg) | 0.160 | 0.200 |
| Aortic diastolic blood pressure (mmHg) | 0.307 | 0.020 * |
| Pulse pressure (mmHg)            | -0.048| 0.704 |
| White blood count (×1000/μL)     | 0.002| 0.987 |
| Hemoglobin (g/dL)                | -0.144| 0.247 |
| Total cholesterol (mg/dL)        | 0.157| 0.209 |
| Triglyceride (mg/dL)             | 0.260| 0.035 * |
| HDL-C (mg/dL)                    | -0.049| 0.698 |
| LDL-C (mg/dL)                    | -0.035| 0.781 |
| Log-glucose (mg/dL)              | -0.014| 0.912 |
| Log-blood urea nitrogen (mg/dL)  | 0.141| 0.260 |
| Log-creatinine (mg/dL)           | 0.006| 0.962 |
| Glomerular filtration rate (mL/min) | -0.239 | 0.054 |
| Total calcium (mg/dL)            | -0.115| 0.356 |
| Phosphorus (mg/dL)               | 0.175| 0.160 |
| Ca × P product (mg^2/dL^2)       | 0.118| 0.347 |
| Log-osteoprotegerin (pg/L)       | 0.462| <0.001 * |
| Log-intact parathyroid hormone (pg/mL) | 0.008 | 0.950 |

*p < 0.05 is considered statistically significant in the univariate linear analyses.

### Table 4

Multivariate stepwise linear regression analysis of body fat mass, aortic diastolic blood pressure, triglyceride, height, body weight, and log-OPG: correlation with aortic augmentation index levels among the 66 renal transplant recipients.

| Variable                         | Beta | R² | R² change | p    |
|----------------------------------|------|----|-----------|------|
| Log-osteoprotegerin (pg/L)       | 0.397| 0.213| 0.213 |<0.001 * |
| Height (cm)                      | -0.260| 0.294 | 0.081 | 0.009 * |
| Aortic diastolic blood pressure (mmHg) | 0.243 | 0.352 | 0.058 | 0.022 * |

*p < 0.05 is considered statistically significant in the multivariate stepwise linear regression analysis.

OPG = osteoprotegerin.
increased with height and SBP in a study based on 3432 participants [18]. However, a recent study noted that age and SBP were not significantly associated with the aortic Aix in renal transplant recipients [19]. The aortic Aix was inversely associated with height in a study on randomly selected community-dwelling adults (N = 1152) [20]. In normal-weight individuals, it was significantly higher in those with metabolic syndrome than in those without the syndrome [21]. Weight loss on a 12-week training program was significantly and independently associated with reduction in Aix values after adjustment for heart rate at 75 beats per minute among Japanese elderly persons [22]. Our study showed that body fat mass, aortic DBP, and TGs were positively correlated, whereas height and body weight were negatively correlated with aortic Aix in renal transplant recipients. However, our study did not find a statistically significant association between aortic Aix values and age in renal transplant recipients. There is a tendency for female renal transplant recipients to have higher aortic Aix values than men, but it just missed statistical significance in our study (p = 0.052). Aortic DBP was positively associated with aortic Aix, whereas height was negatively associated with aortic Aix values among renal transplant recipients in our study after multivariable analysis.

OPG is a vascular calcification inhibitor that strongly inhibits bone resorption [6]. Vascular calcification is an active, complex process that involves numerous mechanisms responsible for calcium deposition in the arterial walls, leading to an increase in arterial stiffness [7,23]. Clinical studies have suggested that an increase in serum OPG levels is associated with renal events, CV events, and mortality in renal transplant recipients [8,9]. A high level of OPG has been significantly associated with the progression of abdominal aortic calcification in renal transplant recipients [24]. The serum OPG level was also positively associated with Aix values in postmenopausal women with osteoporosis [25]. Our study showed that serum log-OPG concentrations were positively correlated with aortic Aix values in renal transplant recipients. This relationship remained significant even after adjustment for several confounders affecting renal transplant recipients.

Our study had some limitations. First, the number of patients enrolled was small, thereby weakening the statistical power of the results. Second, antihypertensive drugs such as β-blockers increase the aortic Aix by decreasing central to brachial amplification [26]. We did not record antihypertension regimens in this study. Further studies are needed to elucidate the causal relationship between serum OPG levels and aortic Aix values in renal transplant recipients.

In conclusion, this study showed positive associations between Aix values and log-OPG and aortic DBP, and a negative association between Aix values and height in renal transplant recipients. We feel further studies and investigations are needed to understand the effects of these factors on Aix values in renal transplant recipients.

Acknowledgments

This study was supported by a grant from Buddhist Tzu Chi General Hospital, Hualien, Taiwan (Grant No. TCRD102-26).

References

[1] Khoshdel AR, Carney SL. Arterial stiffness in kidney transplant recipients: an overview of methodology and applications. Urol J 2008;5:3–14.

[2] Vlahopoulos C, Kaplanteris P, Aboyans V, Brodmann M, Cifkova R, Cosentino F, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the Europe Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015;241:507–32.

[3] Sinner JH, Godtfredsen NJ, Lowe A, M Lambrecht D, M Young J, Love R, et al. Should the augmentation index be normalized to heart rate? J Atheroscler Thromb 2014;21:11–6.

[4] Tomoyama H, Yamashina A. Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J 2010;74:24–31.

[5] Karwowski W, Naumk I, Szczepański M, Myśliwiec M. The mechanism of vascular calcification: a systematic review. Med Sci Monit 2012;18:RA1–R11.

[6] Evrard S, Delanaye P, Karmel S, Cristol JP, Cavalier E. SFBC/SN joined working group on vascular calcifications. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta 2015;438:401–14.

[7] Harvey A, Montezano AC, Tousy RM. Vascular biology of ageing: implications in hypertension. J Mol Cell Cardiol 2015;83:112–21.

[8] Hjelmesaath J, Vetromile F, Kuster N, Barberet J, Dupuy AM, Ribstein J, et al. Central hemodynamics and cardiovascular death in renal transplant patients. J Am Soc Nephrol 2006;17:1466–54.

[9] Svensson M, Dahlke DO, Mäen G, Wehrauch G, Scharnagl H, Daboh H, et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Nephrol Dial Transplant 2012;27:2571–9.

[10] Wang JH, Lee CJ, Chen ML, Yang CF, Chen YC, Hsu BG. Association of serum osteoprotegerin levels with carotid-femoral pulse wave velocity in hypertensive patients. J Clin Hypertens (Greenwich) 2014;16:301–8.

[11] Hsu BG, Shih MH, Chen YC, Ho GJ, Lin TY, Lee MC. High serum osteoprotegerin is associated with arterial stiffness in kidney transplant patients. Toboku J Exp Med 2015;236:247–53.

[12] Lee CJ, Wang JH, Chen ML, Yang CF, Chen YC, Hsu BG. Serum osteoprotegerin is associated with arterial stiffness assessed according to the ankle–knee vascular index in hypertensive patients. J Atheroscler Thromb 2015;22:304–12.

[13] Vlahopoulos C, Azaanouridis K, Stefanidis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318–27.

[14] Verbeke F, Maréchal C, Van Laecke S, Van Biesen W, Devuyt O, Van Bortel LM, et al. Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension 2011;58:831–8.

[15] Vlahopoulos C, Azaanouridis K, Rourke MF, Safar ME, Boa K, Stefanidis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010;31:1855–71.

[16] Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003;107:493–7.

[17] Janner JH, Godtfredsen NS, Ladelund S, Vestbo J, Prescott E. Aortic augmentation index: reference values in a large unselected population by means of the Sphygmocor device. Am J Hypertens 2010;23:180–5.

[18] Janner JH, Godtfredsen NS, Ladelund S, Vestbo J, Prescott E. The association between aortic augmentation index and cardiovascular risk factors in a large unselected population. J Hum Hypertens 2012;26:476–84.

[19] Bargoum AS, Vetromile F, Kuster N, Barberet J, Dupuy AM, Ribstein J, et al. Markers of bone remodeling are associated with arterial stiffness in renal transplant recipients. J Hum Hypertens 2010;24:72–7.

[20] Reeve JC, Abhayaratna WP, Davies JE, Sharman JE. Prediction of cardiovascular events and all-cause mortality with arterial stiffness assessed according to the ankle–knee vascular index in hypertensive patients. J Atheroscler Thromb 2015;22:304–12.

[21] Vlahopoulos C, Azaanouridis K, Stefanidis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318–27.

[22] Verbeke F, Maréchal C, Van Laecke S, Van Biesen W, Devuyt O, Van Bortel LM, et al. Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension 2011;58:831–8.

[23] Vlahopoulos C, Azaanouridis K, Rourke MF, Safar ME, Boa K, Stefanidis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010;31:1855–71.

[24] Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003;107:493–7.

[25] Janner JH, Godtfredsen NS, Ladelund S, Vestbo J, Prescott E. The association between aortic augmentation index and cardiovascular risk factors in a large unselected population. J Hum Hypertens 2012;26:476–84.

[26] Bargoum AS, Vetromile F, Kuster N, Barberet J, Dupuy AM, Ribstein J, et al. Markers of bone remodeling are associated with arterial stiffness in renal transplant recipients. J Hum Hypertens 2010;24:72–7.

[27] Reeve JC, Abhayaratna WP, Davies JE, Sharman JE. Central hemodynamics could explain the inverse association between height and cardiovascular mortality. Am J Hypertens 2014;27:392–400.

[28] Sharogordsky M. Vascular impact of metabolic syndrome in subjects with normal weight, overweight, or obesity: is normal weight sufficient for vascular health? J Am Coll Nutr 2015;34:515–20.

[29] Kawamoto R, Kohara K, Katoh T, Kusunoki T, Ohtsuka N, Abe M, et al. Effect of weight loss on central systolic blood pressure in elderly community-dwelling persons. Hypertens Res 2014;37:933–8.

[30] Persy V, D’Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 2009;15:405–16.

[31] Meneghini M, Regalia A, Aleri C, Barretta F, Croci D, Gandolfo MT, et al. Calcium and osteoprotegerin levels predict the progression of the abdominal aortic calcifications after kidney transplantation. Transplantation 2013;96:32–8.

[32] Sharogordsky M, Boaz M, Luckish A, Matas Z, Gavish D, Mashavi M. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis 2009;204:608–11.

[33] Mancia GH, Hughes AD. Meta-analysis of the comparability of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol 2013;75:79–92.